Wolverine Trading’s Cue Biopharma CUE Stock Holding History

Wolverine Trading’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-573	Closed	-$81K	–	4690
2022 Q1	$81K	Buy	+573	New	+$122K	﹤0.01%	4904

Other funds holding CUE

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Wolverine Trading's CUE Position: Q4 2023 in Review

Wolverine Trading sold out of Cue Biopharma (CUE) in Q4 2023, closing a stake of 371 shares — an estimated $25.6K sold.

Wolverine Trading first reported a position in CUE in Q1 2022 and held it in 2 quarters. The position peaked at $47K in Q1 2022. 80 funds tracked by Wall St. Rank hold CUE as of Q4 2023.

Wolverine Trading reported no remaining Cue Biopharma position as of Q4 2023 after selling out during the quarter.
Wolverine Trading sold 371 Cue Biopharma shares in Q4 2023, an estimated $25.6K.
Wolverine Trading first reported a position in Cue Biopharma in Q1 2022 and held it in 2 quarters.
Wolverine Trading's Cue Biopharma position peaked at $47K in Q1 2022.
80 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2023.

Based on Wolverine Trading's 13F filing for Q4 2023, filed 14 Feb 2024.